Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents

Ingela Loell, Joan Raouf, Yiwen Chen, Rongye Shi, Inger Nennesmo, Helene Alexanderson, Maryam Dastmalchi, Kanneboyina Nagaraju, Marina Korotkova, Ingrid E. LundbergArthritis 2016 · DOI

TL;DR

This study investigates the molecular effects of immunosuppressive treatment on muscle tissue in patients with polymyositis (PM) and dermatomyositis (DM). While treatment successfully reduced inflammation, it also negatively impacted muscle remodeling and lipid metabolism, potentially explaining persistent muscle weakness.

What Problem Does This Paper Address?

Polymyositis (PM) and dermatomyositis (DM) are autoimmune diseases causing chronic muscle inflammation and weakness. Current treatments, primarily high-dose glucocorticoids combined with immunosuppressants, often fail to fully restore muscle function, leaving patients with persistent impairment and side effects. The underlying molecular mechanisms for this incomplete recovery in the target organ (muscle) remain unclear, hindering the development of more effective therapies. This paper aims to elucidate these mechanisms by examining gene expression and protein changes in muscle biopsies before and after treatment.

Methods

The researchers employed a multi-pronged approach:

  • Gene Expression Profiling: They used Affymetrix Human Genome U133 Plus 2.0 microarrays to analyze the expression of thousands of genes in paired muscle biopsies (before and after treatment). This allowed for a broad overview of molecular changes.
  • Western Blot: To validate key gene expression findings at the protein level, Western blots were performed for selected proteins.
  • Histopathology and Immunohistochemistry: Muscle biopsy sections were examined for inflammatory cell infiltration (CD3, CD68), MHC class I expression, and fiber type composition (using mATPase staining).

Statistical analysis, including Wilcoxon signed rank tests, was used to determine the significance of observed changes.

Datasets

The study utilized paired muscle biopsy samples from six adult patients diagnosed with probable or definite DM or PM. These biopsies were collected before and after a median of 8.5 months of conventional immunosuppressive treatment. No new public datasets were introduced.

Key Insights and Ideas

  • Dual Effect of Treatment: Immunosuppressive therapy effectively dampens the inflammatory response in muscle tissue, as evidenced by the downregulation of genes related to immune response and inflammation, including interferon pathways and inflammasome components.
  • Muscle Remodeling Hindered: Despite reducing inflammation, the treatment appears to negatively impact muscle regeneration and growth. This is suggested by changes in genes involved in the ubiquitin-proteasome pathway and structural proteins, alongside an upregulation of myostatin, a negative regulator of muscle growth.
  • Lipid Metabolism Dysregulation: The treatment also alters genes involved in lipid metabolism, potentially leading to increased lipid accumulation and lipotoxicity within muscle cells. This could contribute to impaired muscle function.
  • Fiber Type Shift: A significant shift towards fast-twitch (Type II) muscle fibers was observed post-treatment, which aligns with reduced muscle endurance (as measured by the Functional Index-2) and may be a compensatory mechanism or a consequence of impaired regeneration.

Key Results

  • Inflammation Reduction: Gene Ontology analysis revealed that 39 out of 43 genes associated with immune response and inflammation were downregulated post-treatment. This was confirmed at the protein level for AIM-2 and Caspase-1 (inflammasome components).
  • Muscle Remodeling Changes: Genes related to muscle remodeling showed a mixed but concerning pattern. While some structural protein genes were upregulated, the negative regulator of muscle growth, myostatin, was also upregulated. Protein expression of FKBP5, implicated in muscle tissue remodeling, was significantly increased.
  • Lipid Metabolism Alterations: Genes involved in fatty acid uptake, lipolysis, and lipogenesis were upregulated, suggesting enhanced lipid accumulation. The study predicted an increase in lipid storage (Z-score +2.066).
  • Fiber Type Shift: The percentage of Type I fibers decreased significantly (median 52% to 43%), while Type II fibers increased (median 48% to 57%) after treatment (p < 0.05 for both).
  • Clinical Improvement: While not a complete recovery, two out of six patients showed improvement in Manual Muscle Test (MMT-8), and four improved in the Functional Index-2. However, persistent muscle impairment was noted in most patients.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The study included only six patients, making it difficult to generalize findings.
  • Heterogeneity: The cohort included both PM and DM patients, and the degree of histopathological changes varied, potentially influencing the results.
  • Treatment Inconsistency: While all patients received high-dose glucocorticoids, the specific combination with other immunosuppressants varied based on physician decisions.
  • Biopsy Timing: The 9-month follow-up biopsy might not capture the final repaired muscle but rather the immediate effects of immunosuppression.
  • Exercise Influence: Four out of six patients engaged in regular exercise, which could have counteracted some of the negative treatment effects.
  • Distinguishing Disease vs. Treatment Effects: It's challenging to fully separate the impact of disease progression from the immunosuppressive treatment.

Future work could involve:

  • Replicating these findings in a larger cohort.
  • Investigating the specific contributions of PM versus DM to these molecular changes.
  • Exploring the potential of combining immunosuppressive therapy with targeted interventions for muscle remodeling and lipid metabolism.
  • Using experimental models to better disentangle disease and treatment effects.
  • Further detailed studies on lipid profiles in myositis patients and their relationship to treatment outcomes.

Summary updated

Abstract

The anti-inflammatory effect of immunosuppressive treatment was combined with negative effects on genes involved in muscle tissue remodeling and lipid metabolism, suggesting a negative effect on recovery of muscle performance which may contribute to persisting muscle impairment in adult patients with DM and PM.
BibTeX
@inproceedings{loell2016effects,
  author = {Ingela Loell and Joan Raouf and Yiwen Chen and Rongye Shi and Inger Nennesmo and Helene Alexanderson and Maryam Dastmalchi and Kanneboyina Nagaraju and Marina Korotkova and Ingrid E. Lundberg},
  title = {{Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents}},
  booktitle = {Arthritis},
  year = {2016},
  doi = {10.1186/s13075-016-1033-y},
}
Figure